Chugai Pharmaceutical Co., Ltd. (CHGCF)
USD 43.0
(-7.53%)
USD 43.0
(-7.53%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1111.36 Billion JPY | -11.79% |
| 2022 | 1259.94 Billion JPY | 26.02% |
| 2021 | 999.75 Billion JPY | 27.04% |
| 2020 | 786.94 Billion JPY | 14.68% |
| 2019 | 686.18 Billion JPY | 18.35% |
| 2018 | 579.78 Billion JPY | 8.53% |
| 2017 | 534.19 Billion JPY | 8.63% |
| 2016 | 491.78 Billion JPY | -1.42% |
| 2015 | 498.83 Billion JPY | 8.18% |
| 2014 | 461.1 Billion JPY | 8.84% |
| 2013 | 423.65 Billion JPY | 8.29% |
| 2012 | 391.22 Billion JPY | 4.74% |
| 2011 | 373.51 Billion JPY | -1.58% |
| 2010 | 379.5 Billion JPY | -11.53% |
| 2009 | 428.94 Billion JPY | 31.2% |
| 2008 | 326.93 Billion JPY | -5.18% |
| 2007 | 344.8 Billion JPY | 5.74% |
| 2006 | 326.09 Billion JPY | -0.32% |
| 2005 | 327.15 Billion JPY | 11.02% |
| 2004 | 294.67 Billion JPY | 26.6% |
| 2003 | 232.74 Billion JPY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 236.94 Billion JPY | -13.46% |
| 2024 Q2 | 315.91 Billion JPY | 33.32% |
| 2023 Q3 | 257.89 Billion JPY | -3.56% |
| 2023 Q4 | 273.81 Billion JPY | 6.17% |
| 2023 Q1 | 312.24 Billion JPY | -28.79% |
| 2023 FY | 1111.36 Billion JPY | -11.79% |
| 2023 Q2 | 267.41 Billion JPY | -14.36% |
| 2022 Q4 | 438.49 Billion JPY | 94.64% |
| 2022 Q2 | 235.61 Billion JPY | -34.65% |
| 2022 Q1 | 360.55 Billion JPY | 11.88% |
| 2022 FY | 1259.94 Billion JPY | 26.02% |
| 2022 Q3 | 225.28 Billion JPY | -4.38% |
| 2021 Q2 | 221.41 Billion JPY | 31.15% |
| 2021 Q1 | 168.81 Billion JPY | -19.77% |
| 2021 FY | 999.75 Billion JPY | 27.04% |
| 2021 Q4 | 322.26 Billion JPY | 12.18% |
| 2021 Q3 | 287.26 Billion JPY | 29.74% |
| 2020 Q1 | 179.42 Billion JPY | 1.18% |
| 2020 Q3 | 208.4 Billion JPY | 10.44% |
| 2020 FY | 786.94 Billion JPY | 14.68% |
| 2020 Q4 | 210.42 Billion JPY | 0.97% |
| 2020 Q2 | 188.69 Billion JPY | 5.17% |
| 2019 Q3 | 188.56 Billion JPY | 13.6% |
| 2019 Q2 | 165.99 Billion JPY | 7.59% |
| 2019 FY | 686.18 Billion JPY | 18.35% |
| 2019 Q1 | 154.28 Billion JPY | 0.61% |
| 2019 Q4 | 177.33 Billion JPY | -5.96% |
| 2018 Q3 | 141.31 Billion JPY | 2.63% |
| 2018 Q4 | 153.34 Billion JPY | 8.51% |
| 2018 Q2 | 137.69 Billion JPY | -6.6% |
| 2018 Q1 | 147.42 Billion JPY | 0.6% |
| 2018 FY | 579.78 Billion JPY | 8.53% |
| 2017 Q4 | 146.55 Billion JPY | 8.66% |
| 2017 Q2 | 127.3 Billion JPY | 1.47% |
| 2017 Q1 | 125.46 Billion JPY | -3.68% |
| 2017 FY | 534.19 Billion JPY | 8.63% |
| 2017 Q3 | 134.87 Billion JPY | 5.94% |
| 2016 FY | 491.78 Billion JPY | -1.42% |
| 2016 Q3 | 113.98 Billion JPY | -10.7% |
| 2016 Q2 | 127.63 Billion JPY | 6.46% |
| 2016 Q1 | 119.89 Billion JPY | -8.53% |
| 2016 Q4 | 130.26 Billion JPY | 14.28% |
| 2015 FY | 498.83 Billion JPY | 8.18% |
| 2015 Q4 | 131.06 Billion JPY | 2.72% |
| 2015 Q3 | 127.59 Billion JPY | 3.65% |
| 2015 Q2 | 123.09 Billion JPY | 5.13% |
| 2015 Q1 | 117.08 Billion JPY | -8.3% |
| 2014 Q3 | 111.4 Billion JPY | 13.71% |
| 2014 Q4 | 127.68 Billion JPY | 14.61% |
| 2014 FY | 461.1 Billion JPY | 8.84% |
| 2014 Q1 | 124.04 Billion JPY | 5.91% |
| 2014 Q2 | 97.97 Billion JPY | -21.01% |
| 2013 Q4 | 117.11 Billion JPY | 11.0% |
| 2013 Q3 | 105.51 Billion JPY | -4.6% |
| 2013 FY | 423.65 Billion JPY | 8.29% |
| 2013 Q1 | 90.41 Billion JPY | -21.93% |
| 2013 Q2 | 110.6 Billion JPY | 22.32% |
| 2012 FY | 391.22 Billion JPY | 4.74% |
| 2012 Q1 | 90.25 Billion JPY | -7.43% |
| 2012 Q4 | 115.81 Billion JPY | 28.47% |
| 2012 Q3 | 90.14 Billion JPY | -5.12% |
| 2012 Q2 | 95 Billion JPY | 5.26% |
| 2011 Q4 | 97.49 Billion JPY | 3.63% |
| 2011 FY | 373.51 Billion JPY | -1.58% |
| 2011 Q3 | 94.08 Billion JPY | -2.22% |
| 2011 Q1 | 85.72 Billion JPY | -17.12% |
| 2011 Q2 | 96.21 Billion JPY | 12.24% |
| 2010 Q4 | 103.43 Billion JPY | 10.39% |
| 2010 Q2 | 95.29 Billion JPY | 9.43% |
| 2010 Q1 | 87.08 Billion JPY | -26.96% |
| 2010 FY | 379.5 Billion JPY | -11.53% |
| 2010 Q3 | 93.69 Billion JPY | -1.68% |
| 2009 Q1 | 94.69 Billion JPY | 0.0% |
| 2009 Q3 | 118.02 Billion JPY | 21.67% |
| 2009 Q4 | 119.23 Billion JPY | 1.03% |
| 2009 FY | 428.94 Billion JPY | 31.2% |
| 2009 Q2 | 97 Billion JPY | 2.44% |
| 2008 FY | 326.93 Billion JPY | -5.18% |
| 2007 FY | 344.8 Billion JPY | 5.74% |
| 2006 FY | 326.09 Billion JPY | -0.32% |
| 2005 FY | 327.15 Billion JPY | 11.02% |
| 2004 FY | 294.67 Billion JPY | 26.6% |
| 2003 FY | 232.74 Billion JPY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| AstraZeneca PLC | 46.91 Billion USD | -2268.91% |
| Bristol-Myers Squibb Company PFD CONV 2 | 45 Billion USD | -2369.375% |
| CSPC Pharmaceutical Group Limited | 31.45 Billion USD | -3433.746% |
| Clarus Therapeutics Holdings, Inc. | 13.95 Million USD | -7962692.864% |
| Novartis AG | 46.66 Billion USD | -2281.841% |
| PT Kalbe Farma Tbk. | 1.97 Billion USD | -56052.513% |